Cubist Systematic Strategies, LLC Syros Pharmaceuticals, Inc. Transaction History

Cubist Systematic Strategies, LLC

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.69 - $1.21 $6,400 - $11,223	-9,276 Reduced 45.13%	11,278 $11,000
Q1 2022 May 16, 2022	SELL	$1.02 - $3.8 $4,857 - $18,095	-4,762 Reduced 18.81%	20,554 $24,000
Q4 2021 Feb 14, 2022	SELL	$3.26 - $4.66 $201,057 - $287,400	-61,674 Reduced 70.9%	25,316 $83,000
Q3 2021 Nov 15, 2021	SELL	$4.08 - $5.66 $697,708 - $967,899	-171,007 Reduced 66.28%	86,990 $389,000
Q2 2021 Aug 16, 2021	BUY	$5.01 - $7.48 $1.16 Million - $1.74 Million	231,972 Added 891.34%	257,997 $1.41 Million
Q1 2021 May 17, 2021	SELL	$7.19 - $14.95 $86,905 - $180,700	-12,087 Reduced 31.71%	26,025 $195,000
Q4 2020 Feb 16, 2021	BUY	$6.66 - $14.66 $196,876 - $433,364	29,561 Added 345.7%	38,112 $414,000
Q3 2020 Nov 16, 2020	SELL	$8.69 - $14.47 $91,488 - $152,340	-10,528 Reduced 55.18%	8,551 $76,000
Q2 2020 Aug 14, 2020	BUY	$5.21 - $11.03 $98,536 - $208,610	18,913 Added 11393.37%	19,079 $203,000
Q1 2020 May 15, 2020	BUY	$4.46 - $9.2 $740 - $1,527	166 New	166 $1,000
Q1 2019 May 15, 2019	SELL	$5.51 - $9.59 $2,898 - $5,044	-526 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$5.55 - $11.34 $7,614 - $15,558	-1,372 Reduced 72.29%	526 $3,000
Q3 2018 Nov 14, 2018	SELL	$9.74 - $12.92 $95,130 - $126,189	-9,767 Reduced 83.73%	1,898 $23,000
Q2 2018 Aug 14, 2018	BUY	$10.16 - $13.65 $118,516 - $159,227	11,665 New	11,665 $119,000
Q4 2017 Feb 14, 2018	SELL	$8.45 - $17.48 $85,564 - $177,002	-10,126 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$13.52 - $23.75 $136,903 - $240,492	10,126	10,126 $149,000

Ticker SYRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,236,200
Market Cap $43.1M
Description
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically def...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.